Ratings PolyNovo Limited

Equities

PNV

AU000000PNV0

Market Closed - Australian S.E. Other stock markets 05:05:53 2024-05-23 pm EDT			5-day change	1st Jan Change
2.03 ^AUD	0.00%		-6.02%	+22.66%

May. 08	PolyNovo's Revenue Climbs 68.6% in April	MT
Mar. 04	Polynovo Gets India OK for Listing of Dermal Scaffold Device on Government e-Portal Marketplace	MT

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
The earnings growth currently anticipated by analysts for the coming years is particularly strong.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Over the last twelve months, the sales forecast has been frequently revised upwards.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.

Weaknesses

The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 336.65 times its estimated earnings per share for the ongoing year.
Based on current prices, the company has particularly high valuation levels.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
POLYNOVO LIMITED	+22.66%	944M	C
ABBOTT LABORATORIES	-5.31%	182B	C+
MEDTRONIC PLC	-1.21%	114B	C
BECTON, DICKINSON AND COMPANY	-5.53%	67.76B	A
DEXCOM, INC.	+1.22%	51.91B	B-
CENCORA, INC.	+7.03%	43.23B	B-
HOYA CORPORATION	+6.07%	41.07B	B+
METTLER-TOLEDO INTERNATIONAL, INC.	+21.96%	32.07B	B
TERUMO CORPORATION	+15.86%	25B	A-
ZIMMER BIOMET HOLDINGS, INC.	-4.81%	24.55B	B

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes